Table 1.
Demographic data of the enrolled cases
| Number (percent) | Microvessel density | P | |||
|---|---|---|---|---|---|
| Low (≤20) | High (>20) | ||||
| Histological grade: | Grade 1 | 3 (5.2%) | 3 (7.3%) | ||
| Grade 2 | 30 (51.7%) | 24 (58.5%) | 2 (18.1%) | 0.018** | |
| Grade 3 | 25 (43.1%) | 14 (34.2%) | 9 (81.9%) | ||
| Tumor site: | Right | 24 (41.4%) | 18 | 2 | |
| Left | 33 (56.9%) | 22 | 9 | ||
| Bilateral | 1 (1.7%) | 1 | - | ||
| Tumor size: | <2 cm | 7 (12.1%) | 4 | 1 | |
| 2_5 cm | 39 (67.2%) | 31 | 7 | ||
| >5 cm | 12 (20.7%) | 6 | 3 | ||
| Lymph-vascular invasion: |
Present | 44 (75.9%) | 29 (70.7%) | 10 (90.9%) | 0.17 |
| Not identified | 14 (24.1%) | 12 (29.3%) | 1 (9.1%) | ||
| Perineural invasion: | Present | 22 (37.9%) | 18 (43.9%) | 3 (27.2%) | 0.39 |
| Not identified | 36 (62.1%) | 22 (56.1%) | 7 (63.6%) | ||
| Nipple involvement | Present | 10 (17.2 %) | 5 (12.1%) | 4 (36.3%) | 0.06 |
| Not identified | 48 (82.8%) | 35 (85.3%) | 7 (63.7%) | ||
| Skin involvement | Present | 12 (20.7%) | 7 (17%) | 4 (36.3%) | 0.17 |
| Not identified | 46 (79.3%) | 33 (80.4%) | 7 (63.7%) | ||
| Axillary lymph node involvement: |
Present | 45 (77.6%) | 34 (83%) | 7 (63.7%) | 0.164 |
| Not identified | 13 (22.4%) | 7 (17%) | 4 (36.3%) | ||
| Estrogen receptor: | Positive | 32 (55.2 %) | 26 (63.4%) | 2 (18.1%) | 0.008** |
| Negative | 26 (44.8%) | 15 (36.6%) | 9 (81.9%) | ||
| Progestrone receptor: |
Positive | 33 (56.9%) | 28 (68.2%) | 2 (18.1%) | 0.003** |
| Negative | 25 (43.1%) | 13 (31.8%) | |||
| Her 2: | Positive | 21 (36.2%) | 12 (29.2%) | 6 (54.5%) | 0.118 |
| Negative | 37 (63.8%) | 29 (70.8%) | 5 (45.5%) | ||
| Tumor stage: | 1 | 1 (1.7%) | 1 (2.5%) | 9 (81.9%) | |
| 2 | 31 (53.4%) | 21 (51.2%) | 6 (54.5 %) | 0.886 | |
| 3 | 26 (44.9%) | 19 (46.3%) | 5 (45.5%) | ||
*Her2: Human epidermal growth factor receptor2
**
P value < 0.05 is significant.